• Alias: MSB0010718C
    • Fully human mAb that binds to PD-L1 to selectively prevent the interaction between the PD-1 and 7.1 receptors, resulting in the restoration of antitumor T-cell function
    • FDA approved for metastatic Merkel cell carcinoma and locally, advanced, or metastatic urothelial carcinoma following platinum therapy
    • Recommended dose: 10 mg/kg IV over 60 minutes every 2 weeks until disease progression; should premedicate with acetaminophen and diphenhydramine for the first four infusions
    • Half-life: 6.1 days
    • Side effects: Peripheral edema, hypertension, fatigue, dizziness, skin rash, nausea, diarrhea, hyponatremia, decreased appetite, abdominal pain, transaminitis, arthralgia, fevers
    Other topics in Targeted and Immunotherapy Agents